scholarly journals A DEPRESSION OF CELL-MEDIATED IMMUNITY TO MEASLES ANTIGEN IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

1974 ◽  
Vol 139 (4) ◽  
pp. 1019-1024 ◽  
Author(s):  
Virginia Utermohlen ◽  
John B. Winfield ◽  
John B. Zabriskie ◽  
Henry G. Kunkel
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Measles Virus ◽  
Normal Subjects ◽  
Sensitive Indicator ◽  
Cell Mediated Immunity ◽  
Migration Inhibition ◽  
Systemic Lupus ◽  
Test Response

Using the direct migration inhibition test, response to measles antigen in patients with systemic lupus erythematosus (SLE) was found to be decreased when compared with that of normal subjects. No alteration was observed in similar experiments using parainfluenza type 1 and rubella antigens. The specific decrease in measles antigen effect showed no obvious correlation with activity of SLE or with the presence of lymphocytotoxic antibodies. Whether the specificity of the decrease in reactivity is due to some particular relationship between the measles virus or antigen and SLE, or to the possibility that measles reactivity is a more sensitive indicator of a generalized defect of cell-mediated immunity, remains unclear.

scholarly journals Diet in Rheumatoid Arthritis versus Systemic Lupus Erythematosus: Any Differences?

Nutrients ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 772
Author(s):  
Alessia Alunno ◽  
Francesco Carubbi ◽  
Elena Bartoloni ◽  
Davide Grassi ◽  
Claudio Ferri ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Musculoskeletal Diseases ◽  
Normal Subjects ◽  
Experimental Models ◽  
Systemic Lupus ◽  
History Of ◽  
Indirect Action

In recent years, an increasing interest in the influence of diet in rheumatic and musculoskeletal diseases (RMDs) led to the publication of several articles exploring the role of food/nutrients in both the risk of developing these conditions in normal subjects and the natural history of the disease in patients with established RMDs. Diet may be a possible facilitator of RMDs due to both the direct pro-inflammatory properties of some nutrients and the indirect action on insulin resistance, obesity and associated co-morbidities. A consistent body of research has been conducted in rheumatoid arthritis (RA), while studies in systemic lupus erythematosus (SLE) are scarce and have been conducted mainly on experimental models of the disease. This review article aims to outline similarities and differences between RA and SLE based on the existing literature.

Autoimmune thyroid diseases, autoimmune hepatitis, celiac disease and type 1 diabetes mellitus in pediatric systemic lupus erythematosus: Results from the CARRA Legacy Registry

Lupus ◽  
2020 ◽  
Vol 29 (14) ◽  
pp. 1926-1936
Author(s):  
Ohoud AlAhmed ◽  
Vidya Sivaraman ◽  
Melissa Moore-Clingenpeel ◽  
Stacy P Ardoin ◽  
Sharon Bout-Tabaku ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Autoimmune Thyroid Diseases ◽  
Autoimmune Thyroid ◽  
Pediatric Systemic Lupus Erythematosus ◽  
Over Time ◽  
Lupus Disease Activity

Objective Polyautoimmunity (PA) with systemic lupus erythematosus (SLE) is reported as a poor prognostic factor, but little is known about its effect in childhood-onset SLE (cSLE). We describe PA in cSLE within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry and evaluate its association to lupus disease outcomes. Methods CARRA Legacy Registry is the largest pediatric rheumatology registry that collected data at enrollment and every 6 months thereafter. We describe the co-occurrence of selected autoimmune disorders (autoimmune thyroid diseases, autoimmune hepatitis, celiac disease and type 1 diabetes mellitus) in cSLE. To assess outcomes, we studied measures of lupus disease activity, complications, and patient’s quality of life (QoL). Comparisons by PA status were made using chi-square, Fisher’s exact test, two-sample t-tests, Wilcoxon rank sum tests, and mixed effects models as appropriate. Results 1285 patients met the American College of Rheumatology criteria for SLE. Of those, 388 (30%) had data on comorbidity. The prevalence of PA was 8.8%. Patients with PA reported more hospitalizations and aggressive immunotherapy use. SLEDAI and PGA scores improved over time, but did not differ by PA status. No significant differences were found in QoL measures or their trajectory over time by PA status. Conclusion In cSLE, PA is associated with more hospitalizations and aggressive immunotherapy use. Although lupus disease activity improved over time, patients' QoL neither improved over time nor differed by having other autoimmune disease. Prospective, case-control, long-term follow-up studies on cSLE are needed to validate our results. MeSH Key Indexing Terms Pediatric systemic lupus erythematosus; Autoimmune diseases; Outcome assessment

scholarly journals Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview

Biomedicines ◽  
2020 ◽  
Vol 8 (9) ◽  
pp. 303
Author(s):  
Sandra Rodríguez ◽  
Andrés Muñoz ◽  
Rosa-Helena Bustos ◽  
Diego Jaimes
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Adverse Events ◽  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Cell Mediated Immunity ◽  
Systemic Lupus ◽  
Biological Drugs ◽  
Necrosis Factor Alpha ◽  
Post Marketing

Since we have gained an understanding of the immunological pathophysiology of rheumatic diseases such as rheumatoid arthritis and systemic lupus erythematosus, treatment based on biological drugs has become a fundamental axis. These therapies are oriented towards the regulation of cytokines such as tumour necrosis factor-alpha (TNF-α), interleukin (IL)-6, IL-1, and the modulation of cell-mediated immunity (B cells and T cells) by anti CD20 or anti CTAL-4 agents, and can increase the risk of associated infections or adverse events (AE). In this context, the entry of biotherapeutics represented a challenge for pharmacovigilance, risk management and approval by the main global regulatory agencies regarding biosimilars, where efficacy and safety are based on comparability exercises without being an exact copy in terms of molecular structure. The objective of this review is divided into three fundamental aspects: (i) to illustrate the evolution and focus of pharmacovigilance at the biopharmaceutical level, (ii) to describe the different approved recommendations of biopharmaceuticals (biological and biosimilars) and their use in rheumatic diseases (RDs) such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE) and other less frequent RD like cryopyrin-associated autoinflammatory syndromes (CAPS), and (iii) to identify the main AE reported in the post-marketing phase of RD biopharmaceuticals.

PRESENCE OF THE LUPUS ANTICOAGULANT IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS DOES NOT CAUSE INHIBITION OF PROSTACYCLIN PRODUCTION

1987 ◽  
Author(s):  
M H A Rustin ◽  
H A Bull ◽  
P M Dowd ◽  
D A Isenberg ◽  
M L Snaith ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Lupus Anticoagulant ◽  
Umbilical Vein ◽  
Normal Subjects ◽  
Ionophore A23187 ◽  
Systemic Lupus ◽  
Dependent Inhibition ◽  
Prostacyclin Production ◽  
Thrombotic Tendency

The cause of the thrombotic tendency in patients having the lupus anticoagulant (LA) is unknown. Since inhibition of prostacyclin production by endothelial cells (EC) may be a pathogenetic factor, the effect of sera from normal subjects (NS, n=9), SLE (systemic lupus erythematosus) + LA (n=9) and SLE-LA (n=13) on the production of PGI2 by cultured human EC was studied.Confluent 1° cultures of human umbilical vein EC were incubated with 1, 5, 10 and 20% sera from the above for 24 hours. After stimulation with thecalcium ionophore A23187, 6-keto-PGF1α(the stable metabolite of PGI2) in the supernatant was measured by radioimmunoassay.A dose dependent inhibition of 6-keto-PGF1α was observed with all the sera but only the 10 and 20% sera from patients with SLE-LA produced a significantly greater inhibition than control sera. The mean production of 6-keto-PGFia (ng/104 cells) was 2.278 (NS), 2.6594 (SLE-LA) and 2.1418 (SLE + LA)after incubation with 1% sera for 24 hours. This decreased to 1.3647, 0.6517 and 0.942 respectively following incubation with 20% sera. This represented a 44% (NS), 71% (SLE-LA) and 62% (SLE + LA) inhibition of 6-keto-PGF1α production compared to serum free media.The non-significant reduction in prostacyclin production by sera from patients with SLE and the lupus anticoagulant suggests that other factors are responsible for the thrombotic tendency in these patients.

scholarly journals Systemic Lupus Erythematosus with Multiple Autoimmune Disease Presented with Extensive Peripheral Gangrene

2020 ◽  
Vol 2020 ◽  
pp. 1-5 ◽  
Author(s):  
Tareq Z. Alzughayyar ◽  
Jihad Samer Zalloum ◽  
Mohammad N. Elqadi ◽  
Sadi A. Abukhalaf ◽  
Fawzy M. Abunejma ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Autoimmune Disease ◽  
Lupus Erythematosus ◽  
Diabetes Mellitus Type 1 ◽  
Upper Extremities ◽  
Systemic Lupus ◽  
Skin Change ◽  
Rare Form ◽  
First Case

Systemic lupus erythematosus (SLE) is an autoimmune disease and can be associated with other autoimmune diseases. SLE usually presents with skin change and rarely presents with gangrene. SLE gangrene usually involves the digits of upper extremities. We report the first case of SLE associated with an extremely rare constellation of neuromyelitis Optica (NMO) and diabetes mellitus type 1, presented with a rare form of the SLE gangrene which involves bilateral lower extremities up to midlegs, a case that has not yet been reported in the literature. Although SLE gangrene may respond to immunosuppressants, it has a high risk of complications that can end up with amputations.

Sign in / Sign up

Export Citation Format

Share Document